Dasatinib Solution
Developed to manage chronic myeloid leukaemia; indicated to support effective leukaemia control.
Strengths: 50mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Sprycel
- Therapeutic class
Tyrosine Kinase Inhibitor
- Pharmacological class
BCR-ABL Kinase Inhibitor
- Contraindications
hypersensitivity to active ingredient
- Precautions and warnings
monitor for fluid retention; check for bleeding risk
- Minor side effects
nausea; headache; skin rash
- Moderate side effects
fluid retention; pleural effusion
- Dosage forms
Oral solution
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Bristol-Myers Squibb
- Onset Time
variable
- Duration
long-term maintenance
- Storage instructions
Store at room temperature.
- Drug interactions
ketoconazole; rifampicin
- Age restrictions
Only for adult use.
- Pregnancy and breastfeeding
Pregnancy: must not be used. Breastfeeding: must not be used.
Serious side effects
pulmonary arterial hypertension — requires immediate medical attention; haemorrhage — requires immediate medical attention
Patient summary
Developed to manage chronic myeloid leukaemia; indicated to support effective leukaemia control.
Mechanism of action
A tyrosine kinase inhibitor. It prevents the activity of the BCR-ABL protein, which is responsible for the proliferation of cancerous white blood cells in certain forms of leukaemia.
Dasatinib Solution
Developed to manage chronic myeloid leukaemia; indicated to support effective leukaemia control.
Editorial Notes
- Active ingredient(s): Dasatinib
- Listed indication(s): Chronic Myeloid Leukaemia
Available option
- 1 bottle - 50 mg1365-50-mg-16388